With significant externalisation of manufacturing activity in line with our business strategy, we recognise the importance of working with suppliers to ensure they have ethical standards that are consistent with our own. This incorporates setting environmental standards and working to minimise the environmental footprint of our supply chain.
Since 2005 we have been working with key drug substance suppliers to measure and report the environmental impact of the manufacturing activity they carry out on our behalf. In line with the SHE Strategy adopted in 2010 we have continued this work to report the environmental footprint associated with outsourced drug substance manufacture (intermediates and active pharmaceutical ingredients) and now have performance improvement targets in place with prioritised suppliers. In 2012 this work was extended to include our key formulation and packing suppliers.
The environmental measures we have selected at this time are waste generation, CO2 emissions from energy use and, from 2010, water use.
In addition we understand, and take seriously, concerns about the detections of trace amounts of pharmaceutical residues in the environment. You can read more about our approach here. In 2011 we started sharing our Environmental Reference Concentration (ERC) concept with key outsourced manufacturing partners enabling them to assess risk and manage any emissions of the APIs they manufacture or formulate on our behalf.
Click here for the latest information about our performance in this area.
What's next in this section
We recognise the need to use water responsibly and where possible to minimise the use of water in our facilities.
We believe that our primary responsibility is to, among other things, reduce our carbon footprint by improving our energy efficiency.Read more